Published in Curr Cancer Drug Targets on December 01, 2010
Sorafenib and Temsirolimus in Treating Patients With Recurrent Glioblastoma | NCT00329719
Sorafenib in Newly Diagnosed High Grade Glioma | NCT00884416
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00621686
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma | NCT00093613
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM | NCT00597493
MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget (2014) 1.44
RASGRF2 regulates alcohol-induced reinforcement by influencing mesolimbic dopamine neuron activity and dopamine release. Proc Natl Acad Sci U S A (2012) 1.06
The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia (2015) 0.96
Role of bile salt in regulating Mcl-1 phosphorylation and chemoresistance in hepatocellular carcinoma cells. Mol Cancer (2011) 0.92
Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells. PLoS One (2012) 0.90
Cell-type-dependent thyroid hormone effects on glioma tumor cell lines. J Thyroid Res (2011) 0.84
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. Neurotox Res (2013) 0.81
Biologically targeted therapeutics in pediatric brain tumors. Pediatr Neurol (2012) 0.80
EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci (Elite Ed) (2016) 0.79
Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway. World J Surg Oncol (2012) 0.79
Study of the correlation between H-ras mutation and primary hepatocellular carcinoma. Oncol Lett (2012) 0.79
Low Concentration Microenvironments Enhance the Migration of Neonatal Cells of Glial Lineage. Cell Mol Bioeng (2012) 0.79
miRNA interventions serve as 'magic bullets' in the reversal of glioblastoma hallmarks. Oncotarget (2015) 0.79
Norcantharidin induces growth inhibition and apoptosis of glioma cells by blocking the Raf/MEK/ERK pathway. World J Surg Oncol (2014) 0.78
Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression. PLoS One (2014) 0.77
Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours. Chemother Res Pract (2012) 0.77
miR-98 functions as a tumor suppressor in salivary adenoid cystic carcinomas. Onco Targets Ther (2016) 0.75
Neural stem cells secrete factors facilitating brain regeneration upon constitutive Raf-Erk activation. Sci Rep (2016) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Mechanism of activation of a human oncogene. Nature (1982) 12.09
A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature (1982) 11.92
Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature (1983) 10.64
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol (2008) 7.91
Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature (1982) 6.78
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res (2006) 6.66
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 6.44
A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell (2009) 6.23
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature (1982) 6.09
Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci U S A (1981) 5.51
Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci U S A (1982) 5.39
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet (2000) 5.28
Protein kinase C alpha activates RAF-1 by direct phosphorylation. Nature (1993) 5.23
T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature (1982) 4.54
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol (2006) 3.76
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol (2004) 3.56
Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A (1982) 3.48
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol (2009) 3.32
The ras gene family and human carcinogenesis. Mutat Res (1988) 3.20
Somatic mutations in the neurofibromatosis 1 gene in gliomas and primitive neuroectodermal tumours. Anticancer Res (1996) 3.12
Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med (1995) 2.99
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res (2001) 2.78
Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol (2008) 2.61
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res (2002) 2.45
Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol (2008) 2.40
Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res (2005) 2.33
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene (2009) 2.26
Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res (2001) 2.13
Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer (2006) 2.09
Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology (2009) 2.00
Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol (2009) 1.93
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci U S A (1990) 1.84
Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res (2008) 1.83
Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest (2004) 1.81
Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol Cell Biol (1997) 1.76
Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem (1995) 1.74
Many faces of Ras activation. Biochim Biophys Acta (2008) 1.74
Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. Cancer Res (2005) 1.73
Raf: a strategic target for therapeutic development against cancer. J Clin Oncol (2005) 1.63
PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res (2007) 1.60
The novel Rho-GTPase activating gene MEGAP/ srGAP3 has a putative role in severe mental retardation. Proc Natl Acad Sci U S A (2002) 1.57
Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol Cell Biol (2002) 1.56
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol (2004) 1.55
RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma. Neurology (2005) 1.55
Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol (2008) 1.53
Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. Neuropediatrics (2007) 1.52
Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res (2007) 1.51
Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer (2009) 1.48
RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol (2007) 1.43
Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathol (2010) 1.39
Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol (2004) 1.39
Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia (2008) 1.36
Mouse cells contain two distinct ras gene mRNA species that can be translated into a p21 onc protein. Mol Cell Biol (1982) 1.34
A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion. Cancer Res (2009) 1.33
Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol (2009) 1.32
Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene (2009) 1.31
Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res (2005) 1.30
EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. Curr Mol Pharmacol (2010) 1.29
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther (2006) 1.29
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol (2006) 1.25
Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. Discov Med (2010) 1.22
Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol Histopathol (2007) 1.22
Essential role for Ras signaling in glioblastoma maintenance. Cancer Res (2005) 1.22
Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res (1995) 1.18
RAS: target for cancer therapy. Cancer Invest (2008) 1.18
The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases. Curr Genomics (2010) 1.15
Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. Am J Pathol (2005) 1.15
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther (2006) 1.12
Lapatinib. Nat Rev Drug Discov (2007) 1.10
Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res (1998) 1.10
GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma. Mol Cancer Res (2009) 1.09
Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines. Neurosurg Rev (2008) 1.06
MEGAP impedes cell migration via regulating actin and microtubule dynamics and focal complex formation. Exp Cell Res (2006) 1.05
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res (2007) 1.05
Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand? Mol Cancer Res (2009) 1.03
Raf pathway inhibitors in oncology. Curr Opin Investig Drugs (2003) 1.01
Glioblastoma multiforme and the epidermal growth factor receptor. N Engl J Med (2005) 1.00
Combined inhibition of the phosphatidylinositol 3-kinase/Akt and Ras/mitogen-activated protein kinase pathways results in synergistic effects in glioblastoma cells. Mol Cancer Ther (2006) 0.99
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol (2008) 0.96
Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br J Neurosurg (2009) 0.95
AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res (2006) 0.95
Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther (2006) 0.95
RAF expression in human astrocytic tumors. Int J Mol Med (2009) 0.94
Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Investig Drugs (2008) 0.93
Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies. Clin Cancer Res (2010) 0.93
Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol. Surg Neurol (2006) 0.92
Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res (1998) 0.87